Summary of COVID-19 AER002 studies

1. Peluso et al., An Exploratory, Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of an Anti-SARS-CoV-2 Monoclonal Antibody and Response to Treatment in Individuals With Long COVID (outSMART-LC)

36 patient AER002 late treatment RCT: 6% higher long COVID (p=0.25).
RCT 36 patients showing no improvement in long COVID with AER002.
Oct 2025, NCT05877508, https://clinicaltrials.gov/study/NCT05877508, https://c19p.org/peluso2